Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema

Christos Haritoglou, Aljoscha S Neubauer, Marcus KerntDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyAbstract: Diabetic macular edema (DME) is a potentially sight-threatening disease that predominantly affects patients with type 2 diabetes. The pathogenesis is complex, wi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Haritoglou C, Neubauer AS, Kernt M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2dc073ad8f77414d931f5eba102fc2d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2dc073ad8f77414d931f5eba102fc2d0
record_format	dspace
spelling	oai:doaj.org-article:2dc073ad8f77414d931f5eba102fc2d02021-12-02T00:36:37ZFluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema1177-54671177-5483https://doaj.org/article/2dc073ad8f77414d931f5eba102fc2d02013-03-01T00:00:00Zhttp://www.dovepress.com/fluocinolone-acetonide-and-its-potential-in-the-treatment-of-chronic-d-a12405https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Christos Haritoglou, Aljoscha S Neubauer, Marcus KerntDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyAbstract: Diabetic macular edema (DME) is a potentially sight-threatening disease that predominantly affects patients with type 2 diabetes. The pathogenesis is complex, with many contributing factors involved. In addition to overexpression of vascular endothelial growth factor in the diabetic eye, there is an inflammatory pathway that contributes to the breakdown of the blood-retina barrier and nonperfusion. In addition to vascular endothelial growth factor inhibitors, clinical and experimental investigations underline the great potential of steroids in the treatment of DME. Fluocinolone acetonide is currently the only corticosteroid approved for the treatment of DME in Europe. It is manufactured as an intravitreal insert, releasing fluocinolone acetonide at a rate of 0.2 &micro;g per day. Phase III clinical studies have demonstrated that the beneficial effect of the fluocinolone acetonide insert lasts up to 3 years. Improvement in visual acuity was especially remarkable in patients with a prolonged duration of DME of at least 3 years at the initiation of therapy. Cataract formation occurs in nearly all phakic eyes treated, and needs to be considered when the indication for treatment is made. Given the efficacy versus potential complications of the insert, fluocinolone acetonide represents a promising second-line treatment option in patients with DME. Fluocinolone appears to be especially beneficial for patients whose options for visual recovery have seemed limited up until now.Keywords: diabetic macular edema, fluocinolone acetonideHaritoglou CNeubauer ASKernt MDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 503-509 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Haritoglou C Neubauer AS Kernt M Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
description	Christos Haritoglou, Aljoscha S Neubauer, Marcus KerntDepartment of Ophthalmology, Ludwig-Maximilians-University, Munich, GermanyAbstract: Diabetic macular edema (DME) is a potentially sight-threatening disease that predominantly affects patients with type 2 diabetes. The pathogenesis is complex, with many contributing factors involved. In addition to overexpression of vascular endothelial growth factor in the diabetic eye, there is an inflammatory pathway that contributes to the breakdown of the blood-retina barrier and nonperfusion. In addition to vascular endothelial growth factor inhibitors, clinical and experimental investigations underline the great potential of steroids in the treatment of DME. Fluocinolone acetonide is currently the only corticosteroid approved for the treatment of DME in Europe. It is manufactured as an intravitreal insert, releasing fluocinolone acetonide at a rate of 0.2 &micro;g per day. Phase III clinical studies have demonstrated that the beneficial effect of the fluocinolone acetonide insert lasts up to 3 years. Improvement in visual acuity was especially remarkable in patients with a prolonged duration of DME of at least 3 years at the initiation of therapy. Cataract formation occurs in nearly all phakic eyes treated, and needs to be considered when the indication for treatment is made. Given the efficacy versus potential complications of the insert, fluocinolone acetonide represents a promising second-line treatment option in patients with DME. Fluocinolone appears to be especially beneficial for patients whose options for visual recovery have seemed limited up until now.Keywords: diabetic macular edema, fluocinolone acetonide
format	article
author	Haritoglou C Neubauer AS Kernt M
author_facet	Haritoglou C Neubauer AS Kernt M
author_sort	Haritoglou C
title	Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
title_short	Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
title_full	Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
title_fullStr	Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
title_full_unstemmed	Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
title_sort	fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/2dc073ad8f77414d931f5eba102fc2d0
work_keys_str_mv	AT haritoglouc fluocinoloneacetonideanditspotentialinthetreatmentofchronicdiabeticmacularedema AT neubaueras fluocinoloneacetonideanditspotentialinthetreatmentofchronicdiabeticmacularedema AT kerntm fluocinoloneacetonideanditspotentialinthetreatmentofchronicdiabeticmacularedema
_version_	1718403605746155520

Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema

Ejemplares similares